HSBIO

(From left to right) Nancy Cheng, Executive Director and Head of Operations of Hang Seng Indexes Company; Linda Luk, Executive Director and Product Strategist (ETF) of Hang Seng Indexes Company; Gilbert Lee, Executive Chairman of Hang Seng Indexes Company; Nicholas Ho, Commissioner for Belt and Road of the HKSAR Government; Muzambli Markam, Consul General of Malaysia in Hong Kong SAR and Macao SAR; Philip Lim, Head of Equity Markets and Group Head of Equity Derivatives of Kenanga Investment Bank Berhad ("KIBB"); Kenneth Teoh, Deputy Head of Equity Derivatives and Head of Equity Derivatives Trading of KIBB, and Isabelle Zhen, Head of Group Equity Marketing of KIBB
BiotechnologyCategoriesFinanceIndustriesLatestNewsTrending

Kenanga Brings Hong Kong’s Biotech Boom to Malaysian Investors With New Warrants

The new NagaWarrants give Malaysian investors listed exposure to Hong Kong’s biotech sector after the index gained 64.5% in 2025.

By
Anamika Sahu
- Advertisement -
Ad image